Aminaphtone

Aminaphtone (3-methyl-1,4-dioxo-1,4-dihydro-naphthalene-2-y 4-amino-benzoate), a synthetic molecule ((molecular formula: C18H15NO4) derived from 4-aminobenzoic acid, is a drug approved as an endothelial protective agent in "capillary diseases" and classic chronic venous insufficiency. Aminaphtone significantly protects endothelial permeability and stabilizes endothelial cells organized in capillary structures by modulating VE-cadherin expression. In addition, Aminaphtone modulates the expression of several inflammatory and vasoactive factors. Aminaphtone (Capilarema) is used for the treatment of vascular diseases, especially chronic venous diseases. (Ruaro B et al. 2019)]. To date, Aminaphtone has proven to be a versatile and useful molecule for the treatment of peripheral vascular diseases.

Over the last two decades, several preclinical studies have shown that aminaphtone can affect a broad spectrum of biological mediators involved in the regulation of endothelial homeostasis, such as vasoconstrictor and vasodilator molecules as well as pro-inflammatory and fibrotic cytokines. Therefore, there are a growing number of spontaneous clinical reports on the use of aminaphtone in various clinical conditions, such as idiopathic cyclic edema syndrome, mild bleeding disorders, diabetic nephropathy and Raynaud's syndrome (both primary and secondary to systemic sclerosis, SSc) (Ruaro B et al. 2019).

Aminaphtone, which is approved as an endothelial protective agent for "capillary diseases" and classic chronic venous insufficiency (Bambagiotti-Alberti M et al. 2008; De Anna D et al. 1989).

1. Bambagiotti-Alberti M et al. (2008) 3-Methyl-1,4-dioxo-1,4-dihydro-naphthalen-2-yl 4-amino-benzoate. Acta Crystallogr. Sect. E Struct. Rep. Online 64:o718.
2. De Anna D et al. (1989) Effects of therapy with aminaftone on chronic venous and lymphatic stasis. Minerva Cardioangiol 37:251-254.
3. Gotelli E et al. (2023) A Systematic Review of Aminaphtone from Pathophysiology to Clinical Applications: Focus on New Rheumatological Acquisitions. Pharmaceuticals (Basel) 16:569.
4. Ruaro B et al. (2019) Aminaphtone Efficacy in Primary and Secondary Raynaud's Phenomenon: A Feasibility Study Front Pharmacol 10:293.